Carotuximab (TRC105) is a Along with Decitabine resulted in a more durable anti-leukemic effect in AML xenografts.
[1]. Katarina Tripska , et al. Monoclonal anti-endoglin antibody TRC105 (carotuximab) prevents percholesterolemia and perglycemia-induced endothelial dysfunction in human aortic endothelial cells. Front Med (Lausanne). 2022 Sep 7;9:845918.
[2]. June Baik, et al. Therapeutic effect of TRC105 and decitabine combination in AML xenografts. Heliyon. 2020 Oct 13;6(10):e05242.
















